 | |
| Clinical data | |
|---|---|
| Trade names | Hytrin, Zayasel, others |
| Other names | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693046 |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 90-94% |
| Elimination half-life | 12 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H25N5O4 |
| Molar mass | 387.440 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure.[2] For high blood pressure, it is a less preferred option.[2] It is taken by mouth.[2]
Common side effects include dizziness, headache, tiredness, swelling, nausea, and low blood pressure with standing.[2] Severe side effects may include priapism and low blood pressure.[2] Prostate cancer should be ruled out before starting treatment.[2] It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.[2]
Terazosin was patented in 1975 and came into medical use in 1985.[3] It is available as a generic medication.[4] A month supply in the United Kingdom costs the NHS around £5 as of 2021.[4] In the United States the wholesale cost of this amount is about US$4.50.[5] In 2017, it was the 194th most commonly prescribed medication in the United States, with more than two million prescriptions.[6][7]
References edit
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2020. Retrieved 7 September 2020.
- ^ a b c d e f g "Terazosin Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 7 August 2020. Retrieved 17 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495. Archived from the original on 2019-12-22. Retrieved 2019-02-28.
- ^ a b "7. Genito-urinary system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 833. ISBN 978-0-85711-413-6.
{{cite book}}: CS1 maint: date format (link) - ^ "NADAC". Centers for Medicare and Medicaid Services. 27 February 2019. Archived from the original on 2019-03-06. Retrieved 2019-03-17.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Terazosin - Drug Usage Statistics". ClinCalc. Archived from the original on 8 October 2020. Retrieved 11 April 2020.